Searchable abstracts of presentations at key conferences in endocrinology

ea0032s30.2 | Energy Status and pituitary function | ECE2013

Energy status and glucocorticoid excess

Arvat Emanuela , Karamouzis Ioannis , Berardelli Rita , Picu Andreea , D'Angelo Valentina , Giordano Roberta , Ghigo Ezio

Glucocorticoids (GC) act at different target tissues by binding two different intracellular receptors, the glucocorticoid receptor (GR) and the mineralcorticoid receptor (MR), but the their effects vary considerably between subjects, due to a different sensitivity, which is at least partially, genetically determined. GCs are so named based on their actions on carbohydrate metabolism, namely on insulin-dependent processes. In particular, the effect of GC includes increased hepa...

ea0020p575 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Effect of prolonged treatment with potassium canrenoate, a MR antagonist, on basal and stimulated hypothalamus–pituitary–adrenal (HPA) axis in humans

Berardelli Rita , Marinazzo Elisa , Prats Elisa , Picu Andreea , Giordano Roberta , Ghigo Ezio , Arvat Emanuela

HPA is negatively regulated by glucocorticoid feed-back at hypothalamic, pituitary and hippocampal level by glucocorticoid (GR) and mineralcorticoid (MR) receptors. MR antagonists impair HPA rhythm after acute administration. The aim of this study was to verify HPA activity and glico-insulinemic profile both basally and after acute administration of potassium canrenoate (CAN), before and after chronic treatment. We evaluated ACTH, cortisol (F) and dehydroepiandosterone (DHEA) ...

ea0016p30 | Adrenal | ECE2008

Hormonal, metabolic and bone evaluation in a series of adrenal incidentalomas

Bonelli Lorenza , Giordano Roberta , Balbo Marcella , Berardelli Rita , Marinazzo Elisa , Ghigo Ezio , Arvat Emanuela

Clinically silent adrenal masses discovered by abdominal imaging procedures performed for non-adrenal disorders, i.e. adrenal incidentalomas, have become a common finding in clinical practice and they represent a clinical concern because of the risk not only of malignancy but also of subclinical hormonal hypersecretion (SCS) that represents a new risk factor for cardiovascular diseases and/or osteoporosis. We studied 73 patients (39F, 34M; mean±S.E.M.: 61.6...

ea0016p50 | Adrenal | ECE2008

Metabolic and cardiovascular profile in adult patients with addison's disease under conventional glucocorticoid replacement therapy

Giordano Roberta , Falorni Alberto , Balbo Marcella , Marzotti Stefania , Romagnoli Serena , Marinazzo Elisa , Ghigo Ezio , Arvat Emanuela

Object: In Addison’s disease hydrocortisone or cortisone have so far been used at doses of 30–37.5 mg/day, respectively, though several studies showed that cortisol normal production is about 5.7 mg/m2 (20–25 mg/day of hydrocortisone or cortisone, respectively). Differently from secondary hypoadrenalism, scanty data exist in patients with Addison’s disease on role of conventional glucocorticoid replacement and metabolic and cardiovascular outcome...

ea0014p569 | (1) | ECE2007

Cortisol and dexamethasone exert different negative feedback action in humans

Giordano Roberta , Berardelli Rita , Picu Andreea , Balbo Marcella , Bonelli Lorenza , Barberis Anna , Ghigo Ezio , Arvat Emanuela

HPA response to glucocorticoids (GCs) feedback is usually tested by dexamethasone (DEX), a synthetic GC; it poorly crosses BBB and preferentially activates pituitaric glucocorticoid receptor (GR), with a binding potency to GR 7 fold higher and an anti-inflammatory potency about 35 fold higher than cortisol. Cortisol, which easily penetrates into CNS, could better evaluate the GC feedback by acting also at supra-pituitary level. We studied the effects of 150 min infusion of hyd...

ea0022p601 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Basal and stimulated GH secretion in Cushing's syndrome: effects of ghrelin and GHRH+arginine

Picu Andreea , Marinazzo Elisa , Prodam Flavia , Broglio Fabio , Belcastro Sara , Aimaretti Gianluca , Giordano Roberta , Ghigo Ezio , Arvat Emanuela

GH secretion is usually impaired in active Cushing’s syndrome (CS), due to concomitant mechanisms, including diminished GHRH and/or increased somatostatin release and impaired pituitary somatotrope responsiveness. Differently, IGF1 levels not parallel GH insufficiency in CS, being reported reduced, normal or increased. Both ghrelin and GHRH+arginine (ARG) are powerful GH secretagogues, influenced by age and/or BMI. In 27 CS (42.7±2.9 years, 28.8±0.9 kg/m2</...

ea0016p428 | Neuroendocrinology | ECE2008

Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor (SSRI), during lifespan in humans

Berardelli Rita , Margarito Enrica , Ghiggia Federica , Picu Andreea , Bonelli Lorenza , Balbo Marcella , Giordano Roberta , Bo Mario , Arvat Emanuela

Central serotoninergic activity (CSA) is known to influence the hypothalamus–pituitary–adrenal (HPA) axis, and a CSA loss seems to play a role in human brain aging and in etiology of functional hypercortisolism and depression, whose incidence increase with advancing age. Citalopram (CT), a SSRI, has been considered a good tool to evaluate CSA in humans. Aim of this study was to evaluate the neuroendocrine response to CT in healthy adult subjects during lifespan. We e...

ea0014p506 | (1) | ECE2007

Conventional glucocorticoid replacement therapy in patients with Addison’s disease: effects on metabolic and bone parameters

Balbo Marcella , Giordano Roberta , Bonelli Lorenza , Berardelli Rita , Picu Andreea , Benso Andrea , Bertagna Angela , Ghigo Ezio , Arvat Emanuela

In primary adrenal insufficiency hydrocortisone or cortisone are commonly used at doses of 30–37.5 mg/day as replacement therapy, though recent studies showed that cortisol normal production is about 5.7 mg/m2, equivalent to 20 mg/day of hydrocortisone, suggesting that supraphysiological doses are used. In 19 Addison’s disease patients (8 M, 11 F, 23–71 yr) under conventional glucocorticoid replacement therapy (37.5 mg cortisone/day) with low DHEAS le...

ea0081p401 | Pituitary and Neuroendocrinology | ECE2022

Prevalence, type and evolution of autoimmune diseases with respect to hormone control in patients with cortisol, GH and prolactin hypersecretion

Guaraldi Federica , Zoli Matteo , Arvat Emanuela , De Martin Martina , Pecori Giraldi Francesca , Carla Scaroni , Gori Davide , GIORDANO Roberta , Grottoli Silvia , Ghigo Ezio , Asioli Sofia , Mazzatenta Diego

Background: In vitro and animal experiments have clearly demonstrated that excessive cortisol, GH and prolactin secretion, as well as dopamine agonists (D2As) and somatostatin analogs (SSAs), often prescribed for their treatment, affect the immune response and the onset/evolution of autoimmune diseases (AIDs) through direct and indirect complex mechanisms. Data from clinical studies are very scanty.Study aim: To assess the 1) distribution of AIDs accordi...

ea0022p3 | Adrenal | ECE2010

Glucocorticoid receptor polymorphisms and metabolic-cardiovascular impairment in adult patients with Addison's disease under glucocorticoid replacement therapy

Giordano Roberta , Falorni Alberto , Mandrile Giorgia , Gioachino Daniela , Balbo Marcella , Berardelli Rita , Karamouzis Ioannis , Marinazzo Elisa , Picu Andreea , Marzotti Stefania , Romagnoli Serena , Ghigo Ezio , Arvat Emanuela

Object: In Addison’s disease (AD), although glucocorticoid (GC) replacement is essential for health and, indeed, life, several studies showed that conventional GCs doses are involved in metabolic and cardiovascular alterations observed in this disease. As the effects of GCs are mediated by the glucocorticoid receptor (GR), encoded by NR3C1 gene, different polymorphisms in the NR3C1 gene have been linked to altered glucocorticoid sensitivity in general population as well a...